Medical

Data from a 26-week head-to-head Phase 3 study show that the Ultibro Breezhaler indacaterol/glycopyrronium DPI produced greater improvement in the lung function of COPD patients with or without a history of moderate-to-severe exacerbations compared to… Read more . . .

NanoBio Corporation has announced that it will present promising pre-clinical study data of its nano-emulsion (NE)-adjuvanted intranasal herpes simplex virus-2 (HSV-2) vaccine at the Annual Conference on Vaccine Research. NanoBio Senior VP of Vaccine Research… Read more . . .

Civitas Therapeutics has announced positive results from a Phase 2b trial of its CVT-301 inhaled L-dopa for the treatment of Parkinson’s disease symptoms. The company is developing CVT-301 based on its proprietary ARCUS particle engineering… Read more . . .

Genoa Pharmaceuticals has announced that studies conducted in conjunction with McMaster University have shown that peak pirfenidone activity can be achieved by lung levels of the drug that remain for only a short period of… Read more . . .

Researchers from the University of St. Andrews, the University of Edinburgh, and St. Jude’s Children’s Research Hospital have published data demonstrating that a nasal spray designed to prevent the influenza virus from binding with receptors… Read more . . .

Researchers from the Icahn School of Medicine at Mount Sinai have demonstrated that a single 50 mg dose of a ketamine nasal spray could alleviate depressive symptoms in patients with treatment-resistant major depressive disorder within… Read more . . .

Insmed has announced that in a Phase 2 clinical trial of Arikayce (formerly Arikace) inhaled liposomal amikacin for nontuberculous mycobacterial (NTM) lung infections, the product failed to produce a statistically significant reduction in mycobacterial density;… Read more . . .